Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. | Over the last ...

Novotech, a top global clinical trial provider, partners with biotech and pharma to speed siRNA therapeutic development.

Small interfering RNA (siRNA), the molecules that mediate RNAi ... Alnylam’s ability to discover and develop novel drug candidates and delivery approaches and successfully demonstrate the ...

Fungal infections are on the rise globally. According to a study by the Manchester Fungal Infection Group, in 2022, ...

Along with tafamidis and acoramidis, the drug is now the third for ATTR-CM, but it comes with a whopping price tag of ...

Sanofi SA gained U.S. FDA approval for fitusiran as a first-in-class siRNA therapy for hemophilia. Branded Qfitlia, the antithrombin-lowering therapy is indicated for use as a prophylactic treatment ...

The study demonstrates that this RNAi approach shuts down vital fungal genes, thereby inhibiting pathogen growth - a ...

Rona Therapeutics Inc., a global leader in RNA-targeted therapeutics, announced the clearance of an Investigational New Drug (IND) by the U.S. Food and Drug Administration (FDA) for RN0361-an APOC3 ...

With the FDA approval of multiple siRNA-based drugs, including ONPATTRO™ (Patisiran ... and scientific advisory company that provides biotech and small- to mid-sized pharma companies an ...

Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company, has released its newest preclinical report exploring the evolving landscape of ...